Literature DB >> 9018129

Analysis of mutations within the cytoplasmic domain of the Moloney murine leukemia virus transmembrane protein.

A Thomas1, K D Gray, M J Roth.   

Abstract

The role of the cytoplasmic tail of the Moloney murine leukemia virus transmembrane protein in the regulation of syncytia was examined. Three mutations within the cytoplasmic tail were studied. Linker-insertion in7705-12a is within the viral-associated cytoplasmic tail, linker-insertion in7748-12a is within the R peptide, and a third mutation expresses TM lacking the R peptide (Env R-). The Env R- construct was nonviable in Rat1 cells, however, rapidly reverted to a form containing the R peptide when passaged in NIH/3T3 cells. in7705-12a was temperature-sensitive in Rat1 cells, as previously characterized, but was viable at either temperature in NIH/3T3 cells. in7748-12a was comparable with wild-type M-MuLV. The ability of the env constructs to form large multinucleated syncytia with NIH/3T3 and XC cells were examined using transient expression assays, eliminating reversion events due to viral passage and reverse transcription. The Env R- constructs formed syncytia with NIH/3T3 cells. in7705-12a displays enhanced proteolytic cleavage of the R peptide. Neither linker-insertion mutation in7705-12a or in7748-12a activated fusion with NIH/3T3, despite the abundance of processed TM with in7705-12a. All three mutants were fusion competent with Rat XC cells, even in the absence of any cleavage of the R peptide. These results provide insights regarding steric and the temporal affects of cleavage of the R peptide and the assembly of a fusion competent oligomer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018129     DOI: 10.1006/viro.1996.8333

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Characterization of a cytolytic strain of equine infectious anemia virus.

Authors:  Wendy Maury; Patrick J Wright; Sarahann Bradley
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Murine leukemia virus R Peptide inhibits influenza virus hemagglutinin-induced membrane fusion.

Authors:  Min Li; Zhu-Nan Li; Qizhi Yao; Chinglai Yang; David A Steinhauer; Richard W Compans
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression.

Authors:  Min Li; Chinglai Yang; Suxiang Tong; Armin Weidmann; Richard W Compans
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein.

Authors:  S M Rothenberg; M N Olsen; L C Laurent; R A Crowley; P O Brown
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Two distinct mechanisms regulate recruitment of murine leukemia virus envelope protein to retroviral assembly sites.

Authors:  Tiffany M Lucas; Terri D Lyddon; Sarah A Grosse; Marc C Johnson
Journal:  Virology       Date:  2010-07-23       Impact factor: 3.616

6.  Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide.

Authors:  M Li; C Yang; R W Compans
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Moloney murine leukemia virus envelope protein subunits, gp70 and Pr15E, form a stable disulfide-linked complex.

Authors:  D J Opstelten; M Wallin; H Garoff
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  G541R within the 4070A TM protein regulates fusion in murine leukemia viruses.

Authors:  Lucille O'Reilly; Monica J Roth
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide.

Authors:  Hector C Aguilar; W French Anderson; Paula M Cannon
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.